Aceta-PD Pediatric Drops 80 mg/ml

Aceta-PD Pediatric Drops is a trusted paracetamol formulation from Biopharma Limited, designed specifically for children’s pain and fever management. Containing 80 mg/ml of paracetamol, this oral suspension offers rapid relief from multiple discomforts while ensuring pediatric safety.

Priced at ৳30.00 per unit, this cost-effective solution treats fever, post-vaccination pain, teething issues, and inflammatory conditions. The pediatric drops format allows precise dosing for infants as young as 3 months, making it a preferred choice for Bangladeshi parents.

Key therapeutic benefits:

• Blocks pain signals by inhibiting COX enzymes in CNS
• Reduces fever through hypothalamic regulation
• Minimal gastric irritation compared to NSAIDs

The dosage regimen varies by age:

• Below 3 months: 0.5 ml (40 mg) quad-daily
• 4-11 months: 1 ml (80 mg) quad-daily
• 1-2 years: 1.5 ml (120 mg) quad-daily

Patients should avoid concurrent use with barbiturates or alcohol due to hepatotoxicity risks. As part of Biopharma Limited‘s quality range, these drops maintain strict stability when stored properly in amber bottles away from moisture.

Dosage: Up to 3 months: 0.5 ml (40 mg) 4 times daily. 4-11 months: 1 ml (80 mg) 4 times daily. 1-2 years: 1.5 ml (120 mg) 4 times daily. Reduce dose in renal/hepatic impairment. Can be taken with/without food. Maximum treatment duration: 10 days.

Side effects of Aceta-PD are usually mild, though haematological reactions including thrombocytopenia, leucopenia, pancytopenia, neutropenia, and agranulocytosis have been reported. Pancreatitis, skin rashes, and other allergic reactions occur occasionally.

Pregnancy category B. Safe during lactation in therapeutic doses. Consult physician for prolonged use.

Monitor liver function in chronic alcohol users. Avoid concurrent use with other paracetamol-containing products. Pediatric drops require precise measurement.

Pediatrics: Use under medical supervision below 3 months. Elderly: Standard dose applicable. Hepatic impairment: Reduce dose by 50%. Renal impairment: Extend dosing interval.

Liver damage is possible in adults who have taken 10 g or more of Aceta-PD. Ingestion of 5 g or more of Aceta-PD may lead to liver damage if the patient has following risk factors: If the patient is on long term treatment with Carbamazepine, Phenobarbitone, Phenytoin, Primidone, Rifampicin, St John’s Wort or other drugs that induce liver enzymes, or regularly consumes Ethanol in excess of recommended amounts, or is likely to be Glutathione deplete e.g. eating disorders, cystic fibrosis, HIV infection, starvation, cachexia.

Symptoms: Symptoms of Aceta-PD overdose in the first 24 hours are pallor, nausea, vomiting, anorexia and abdominal pain. Liver damage may become apparent 12 to 48 hours after ingestion. Abnormalities of glucose metabolism and metabolic acidosis may occur. In severe poisoning, hepatic failure may progress to encephalopathy, haemorrhage, hypoglycaemia, cerebral oedema and death. Acute renal failure with acute tubular necrosis, strongly suggested by loin pain, haematuria and proteinuria, may develop even in the absence of severe liver damage. Cardiac arrhythmias and pancreatitis have been reported. Immediate treatment is essential in the management of Aceta-PD overdose. Treatment with activated charcoal should be considered if the overdose has been taken within 1 hour. Plasma Aceta-PD concentration should be measured at 4 hours or later after ingestion (earlier concentrations are unreliable). Treatment with N-acetylcysteine may be used up to 24 hours after ingestion of Aceta-PD. However, the maximum protective effect is obtained up to 8 hours post-ingestion. The effectiveness of the antidote declines sharply after this time. If required the patient should be given intravenous N-acetylcysteine, in line with the established dosage schedule. If vomiting is not a problem, oral Methionine may be a suitable alternative for remote areas, outside hospital. Management of patients who present with serious hepatic dysfunction beyond 24 hours from ingestion should be discussed with the NPIS or a liver unit.